Q Chip receives $3M of funding; Vyteris merges with MediSync

> Q Chip, a Cardiff, Wales-based company developing sustained release injectable depot formulations, has reached the first close of $3 million of a planned $4.6 million funding round. The money will go toward scale-up of its Q-Sphera technology Q-Chip has raised about $11.5 million to date. Q Chip release

> Vyteris, a New Jersey-based drug-delivery technology company, has taken on MediSync BioServices as a wholly owned subsidiary. MediSync’s specialty is product development, clinical trial management, and data management services for the biotech industry. Vyteris release

> Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies. Report

> A Czech on progress in drug delivery. Radio Report

Drug delivery patent application of the week: Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye. Application

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.